Innate Pharma (IPHA) news
Recent news
Swedish Orphan Biotriment - Innate eligible for up to $40 mln in near-term development milestones connected to Sezary syndrome
Innate Pharma has made significant progress in its clinical development pipeline for lacutamab, an anti-KIR3DL2 antibody targeting Sézary syndrome, a rare and aggressive form of cutaneous T-cell lymphoma (CTCL). The company is currently preparing for the initiation of the TELLOMAK-3 Phase 3 trial…
AInvest Wire · Aug 10, 2026Sobi will pay Innate Pharma $75M
AInvest Wire · Aug 10, 2026Innate Pharma - preliminary data from 76 patients expected by year-end
AInvest Wire · Jul 21, 2026Innate Pharma - IPH4502 shows favorable safety profile with hematological toxicity to date
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has reported that its investigational Antibody Drug Conjugate (ADC), IPH4502, has demonstrated a favorable safety profile in early clinical trials, with primary observed adverse event . The drug is currently being evaluated in a Phase 1 trial…
AInvest Wire · Jul 21, 2026Hong Kong Intl Airport Operations to Be Affected by Wipha
Hong Kong Intl Airport Operations to Be Affected by Wipha Hong Kong International Airport, one of the busiest transportation hubs in Asia, is expected to face significant disruptions due to the approaching Typhoon Wipha. The storm, which is rapidly intensifying as it moves towards the Guangdong…
AInvest Wire · Jul 19, 2025Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.